Followers | 21 |
Posts | 355 |
Boards Moderated | 0 |
Alias Born | 02/26/2012 |
Thursday, September 15, 2022 1:14:59 PM
Recent SHPH News
- Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
- Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/22/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 11:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:00:16 PM
- Shuttle Pharma Announces Its Intent to Pursue a Rights Offering • PR Newswire (US) • 02/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:25:13 PM
- Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/23/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:05:10 PM
- Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma • PR Newswire (US) • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:51:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 02:00:12 PM
- Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma • PR Newswire (US) • 12/11/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 02:00:25 PM
- Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update • PR Newswire (US) • 11/14/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:21:44 PM
- Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement • PR Newswire (US) • 10/31/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:14:44 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 10/20/2023 08:15:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 08:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 01:00:17 PM
- Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference • PR Newswire (US) • 10/10/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:10:15 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM